FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX
Links:
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor pr…
https://www.jnj.com/media-center/press-releases/fda-approves-label-expansion-ce…
May-29-2026
